1. Home
  2. CINGW vs NTES Comparison

CINGW vs NTES Comparison

Compare CINGW & NTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • NTES
  • Stock Information
  • Founded
  • CINGW N/A
  • NTES 1997
  • Country
  • CINGW United States
  • NTES China
  • Employees
  • CINGW 13
  • NTES N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • NTES Computer Software: Prepackaged Software
  • Sector
  • CINGW Health Care
  • NTES Technology
  • Exchange
  • CINGW Nasdaq
  • NTES Nasdaq
  • Market Cap
  • CINGW N/A
  • NTES N/A
  • IPO Year
  • CINGW 2021
  • NTES 2000
  • Fundamental
  • Price
  • CINGW $0.05
  • NTES $89.36
  • Analyst Decision
  • CINGW
  • NTES Strong Buy
  • Analyst Count
  • CINGW 0
  • NTES 7
  • Target Price
  • CINGW N/A
  • NTES $107.29
  • AVG Volume (30 Days)
  • CINGW N/A
  • NTES 1.6M
  • Earning Date
  • CINGW N/A
  • NTES 11-14-2024
  • Dividend Yield
  • CINGW N/A
  • NTES 1.94%
  • EPS Growth
  • CINGW N/A
  • NTES 3.25
  • EPS
  • CINGW N/A
  • NTES 1.21
  • Revenue
  • CINGW N/A
  • NTES $15,067,016,873.00
  • Revenue This Year
  • CINGW N/A
  • NTES $4.60
  • Revenue Next Year
  • CINGW N/A
  • NTES $8.07
  • P/E Ratio
  • CINGW N/A
  • NTES $14.68
  • Revenue Growth
  • CINGW N/A
  • NTES 3.94
  • 52 Week Low
  • CINGW N/A
  • NTES $75.85
  • 52 Week High
  • CINGW N/A
  • NTES $114.50
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • NTES 60.81
  • Support Level
  • CINGW N/A
  • NTES $85.94
  • Resistance Level
  • CINGW N/A
  • NTES $88.85
  • Average True Range (ATR)
  • CINGW 0.00
  • NTES 1.88
  • MACD
  • CINGW 0.00
  • NTES 0.65
  • Stochastic Oscillator
  • CINGW 0.00
  • NTES 95.54

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: